EXAS Stock Analysis: Buy, Sell, or Hold?
EXAS - Exact Sciences Corp
$104.91
0.99 (0.95%)
▲
5d:
+1.29%
30d:
+1.57%
90d:
+3.15%
BUY
MODERATE Confidence
Analysis Updated: Mar 20, 2026 12:00 AM ET
Earnings: May 07, 2026
Get Alerted When EXAS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: EXAS shows positive signals but monitor for confirmation. Market pricing in 11.1% decline. Moderate conviction.
💡 BUY OPPORTUNITY: EXAS shows positive signals but monitor for confirmation. Market pricing in 11.1% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$91.53
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$56.83
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: EXAS is currently trading at $104.91, which is considered extended relative to its 30-day fair value range of $103.19 to $103.92. From a valuation perspective, the stock is trading at a discount (Forward PE: 55.8) compared to its historical average (79.4). Remarkably, the market is currently pricing in an annual earnings decline of 11.1% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, EXAS is in a strong downtrend. The price is currently testing key support at $103.22. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: EXAS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, EXAS is in a strong downtrend. The price is currently testing key support at $103.22. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: EXAS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$103.19 -
$103.92
Company Quality Score
65/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
65.4%
Protect Your Profits
EXAS is technically overbought (RSI 76). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($105.81)
Fair Price Analysis
30-Day Fair Range
$103.19 -
$103.92
Current vs Fair Value
EXTENDED
Expected Move (7 Days)
±$1.89
(1.8%)
Support & Resistance Levels
Support Level
$103.22
Resistance Level
$104.98
Current Trend
Strong Downtrend
Technical data as of
Mar 20, 2026
Fundamental Context
Forward P/E (Next Year Est.)
55.80
Wall Street Target
$105.81
(+0.9%)
Revenue Growth (YoY)
23.1%
Profit Margin
-6.4%
Valuation Discount vs History
-11.1% cheaper
PE vs Historical
55.8 vs 79.4
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-11.1%
(market-implied from PE analysis)
1-Year Target
$94.42
(-10%)
2-Year Target
$84.98
(-19%)
3-Year Target
$76.48
(-27%)
3-Yr Target (if PE normalizes)
(PE: 56→79)
$108.82
(+4%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 55.8, Growth: 65.6%)
$354.07
(+238%)
Base:
(SPY PE: 22.4, Growth: 65.6%)
$142.00
(+35%)
Bear:
(PE: 19.0, Growth: 65.6%)
$120.70
(+15%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 55.8 to 79.4
Stabilization Target:
$149.27
(+42.3%)
PE Expansion Potential:
+42.3%
Share & Embed Analysis
Last updated: March 30, 2026 3:32 PM ET
Data refreshes hourly during market hours. Next update: 4:32 PM
Data refreshes hourly during market hours. Next update: 4:32 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EXAS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Jacob A Orville
SELL
5000 shares
2025-11-19
Brian Baranick
SELL
2858 shares
2025-11-04
James Edward Doyle
SELL
2000 shares
2025-10-09
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$664 | 60 BUY |
|
DHR
Danaher Corporation |
STRONG BUY
26 analysts |
$265 | 61 BUY |
|
GH
Guardant Health Inc |
STRONG BUY
24 analysts |
$133 | 56 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$261 | 54 HOLD |
|
IQV
IQVIA Holdings Inc |
BUY
23 analysts |
$236 | 61 BUY |
Advanced EXAS Option Strategies
Professional options setups generated by AI based on today's EXAS price and gamma walls.
